Their Brazilian branch, Promediol do Brasil Ltda, is approved by Anvisa and handles operations in Latin America.
Promediol full-spectrum cannabis extract was among the first prescription products authorized by Anvisa for marketing in Brazil.
Currently Promediol do Brasil has registered two products in Brazil: Promediol Full Spectrum Cannabis Extract and Promediol CBD Isolate with different presentations. Promediol products are marketed by Biolab Sanus, a leading pharmaceutical company in the Brazilian market for prescription drugs. Several new products are at various stages of development and will be soon submitted to the health authority for evaluation.
Promediol SA is interested in establishing alliances with strategic partners aimed at developing business in other Countries worldwide.
Promediol SA
Promediol SA is a Swiss company that deals with the research, production and marketing of pharmaceutical grade products based on cannabis for the treatment of various pathologies, especially in the neurological field.
For some years now the company has been exporting and selling their prescription drugs to several countries.
Promediol SA operates in full compliance with GMP and GDP rules.
Activities
Main Activity
Development
Co-development
Trading
API Manufacturing
Extracts
Isolates
Therapeutic Areas
CNS
Dermatology
Mental health
Pain
Rheumatology
Markets
LATAM
MENA
BRICS
ASEAN
Drug Stages
Pre-clinical (Partial)
Clinical Phase I/Phase III (Partial)
Phase I - Phase III (Partial)
Drug Product Forms
Oral (liquid)
Topical
Certifications
Swissmedic
GMP
Anvisa
